Vitrolife AB (CHIX:VITRS) Total Equity: kr8,071 Mil (As of Mar. 2026)


CHIX:VITRS Vitrolife AB CHIX:VITRS
81 GF Score
Price kr105.75
GF Value kr163.33
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Vitrolife AB Total Equity?

Vitrolife AB CHIX:VITRS 81 Total Equity is kr8,071 Mil as of Mar. 2026. GuruFocus rates CHIX:VITRS with a GF Score™ of 81/100 and a GF Value™ of kr163.33 (Possible Value Trap). The stock has 6 warning signs investors should review.

Vitrolife AB's total equity for the quarter that ended in Mar. 2026 was kr8,071 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Vitrolife AB Total Equity Historical Data

* Premium members only.

The historical data trend for Vitrolife AB's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitrolife AB Total Equity Chart

Vitrolife AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15,341.00 16,740.00 12,723.00 13,641.00 7,895.00

Vitrolife AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13,127.00 13,282.00 13,301.00 7,895.00 8,071.00
CHIX:VITRS
81GF Score
Vitrolife AB CHIX:VITRS
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vitrolife AB Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Vitrolife AB's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=11124-3229
=7,895

Vitrolife AB's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=11242-3171
=8,071

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of kr8,071 Mil mean?
Vitrolife AB (CHIX:VITRS) has a Total Equity of kr8,071 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Vitrolife AB and its competitors.
Is Vitrolife AB's Total Equity too high?
Vitrolife AB's current Total Equity is kr8,071 Mil. Overall, Vitrolife AB has a GF Score™ of 81/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Total Equity compare to ABT and SYK?
Vitrolife AB's Total Equity of kr8,071 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Vitrolife AB and its competitors. Vitrolife AB's current Total Equity is kr8,071 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (CHIX:VITRS) is currently considered Possible Value Trap. The stock's GF Value™ is kr163.33, compared to a current price of kr105.75 — trading 35.3% below its estimated fair value. The current Total Equity is kr8,071 Mil. Vitrolife AB's overall GF Score™ is 81/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current Total Equity is kr8,071 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?

Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued. The current stock price of kr105.75 is trading 35.3% below its estimated GF Value™ of kr163.33. GuruFocus considers Vitrolife AB to be Possible Value Trap.

Key valuation signals for CHIX:VITRS:

  • Total Equity: kr8,071 Mil
  • GF Value™: kr163.33 vs. price of kr105.75 (35.3% below fair value)
  • GF Score™: 81/100 with 6 warning signs

No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vitrolife AB Business Description

Address Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
81GF Score

Get the complete analysis for CHIX:VITRS

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr105.75
Price
kr163.33
GF Value